Neoleukin Therapeutics (NLTX) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NLTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLTX, but not buy additional shares or sell existing shares.
View NLTX analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 1 year target prices for Neoleukin Therapeutics' shares. Their NLTX share price forecasts range from $7.50 to $7.50. On average, they expect the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 86.1% from the stock's current price.
View analysts price targets for NLTX or view top-rated stocks among Wall Street analysts.

Neoleukin Therapeutics' stock was trading at $2.5450 at the start of the year. Since then, NLTX shares have increased by 58.3% and is now trading at $4.03.
View the best growth stocks for 2023 here.

Neoleukin Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 43,000 shares, a decrease of 63.5% from the August 31st total of 117,900 shares. Based on an average daily volume of 60,700 shares, the short-interest ratio is currently 0.7 days. Currently, 0.1% of the shares of the stock are sold short.
View Neoleukin Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our NLTX earnings forecast.

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) posted its earnings results on Thursday, August, 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.55.

Neoleukin Therapeutics's stock reverse split on the morning of Monday, September 25th 2023. The 1-5 reverse split was announced on Friday, September 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), RTX (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD).

Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."

Neoleukin Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.19%), Western Standard LLC (1.96%), BlackRock Inc. (1.13%) and Privium Fund Management B.V. (0.27%). Insiders that own company stock include Bros Advisors Lp Baker, Carl Walkey, Jonathan G Drachman, Priti Patel, Robert Ho and Sean Michael Smith.
View institutional ownership trends.

Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NLTX stock can currently be purchased for approximately $4.03.

Neoleukin Therapeutics (NASDAQ:NLTX) has a market capitalization of $35.46 million. The company earns $-57,560,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis.

Neoleukin Therapeutics' mailing address is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. The official website for the company is www.neoleukin.com. The company can be reached via phone at (866) 245-0312, via email at investors@neoleukin.com, or via fax at 778-331-4486.